Active, Not Recruiting
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT06242834
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- University of Iowa Iowa City, Iowa, United States